Evidence map›Paper›PMID 21877179›Full record

ArticleInfection2012

First case of anti-ganglioside GM1-positive Guillain-Barré syndrome due to hepatitis E virus infection.

I Maurissen, A Jeurissen, T Strauven, D Sprengers, B De Schepper

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Infection, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Guillain-Barré and Miller Fisher syndromes in patients with anti-hepatitis E virus antibody: a hospital-based survey in Japan.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016
    Article
  17. Hepatitis E virus and neurological injury.Nature reviews. Neurology · 2016
    Review
  18. Review
  19. Guillain-Barré syndrome and encephalitis/encephalopathy of a rare case of Northern China acute severe hepatitis E infection.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

I MaurissenDepartment of Hepato-Gastroenterology, GZA St. Augustinus, Oosterveldlaan 24, 2610, Wilrijk, Belgium. Isabelle.maurissen@telenet.be
A Jeurissen
T Strauven
D Sprengers
B De Schepper
GZA Ziekenhuizen Campus Sint-Augustinus · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 51-year-old previously healthy woman presented with Guillain-Barré syndrome (GBS) and elevated liver enzymes. Further diagnostic investigations showed the presence of an acute hepatitis E infection associated with anti-ganglioside GM1 antibodies. After treatment with intravenous immunoglobulins, the patient made a rapid recovery. Here, we report the first case of GBS due to acute hepatitis E virus (HEV) infection associated with the presence of anti-ganglioside GM1 antibodies. We also review available literature on the association between acute HEV infection and GBS.

Indexed as

Antibodies, ViralFemaleG(M1) GangliosideGuillain-Barre SyndromeHepatitis EHepatitis E virusHumansImmunoglobulin GImmunoglobulin MImmunoglobulins, IntravenousMiddle AgedReverse Transcriptase Polymerase Chain ReactionTreatment OutcomeAntibodies, ViralG(M1) GangliosideImmunoglobulin GImmunoglobulin MImmunoglobulins, Intravenous

Identifiers

PMID21877179
OpenAlexW1991627692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.